[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601218":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":40,"collaborators":11,"id":42,"slug":11,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":11,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":11,"enrollmentInfo":50,"targetDuration":11,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":11,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with malignant tumors of the gastrointestinal tract","EXPERIMENTAL",null,[13],"Drug: Technetium [99mTc]-H7ND injection",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","Technetium [99mTc]-H7ND injection","Technetium \\[99mTc\\]-H7ND injection is a radiolabeled fibroblast activation protein inhibitor",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Hongcheng Shi","CONTACT","021-64041990","shi.hongcheng@zs-hospital.sh.cn",[27],{"facility":28,"status":29,"city":30,"state":11,"zip":11,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Zhongshan Hospital Affiliated to Fudan University","RECRUITING","Shanghai","China",{"type":33,"coordinates":34},"Point",[35,36],121.45806,31.22222,{"lat":36,"lon":35},[39],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"type":41,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100601218",false,"NCT07107633","A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.","A Multicenter, Open-access, Self-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mTc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignancies.","Inclusion Criteria:\n\nOnly those who meet all the following requirements are eligible to join the group:\n\n1. Adults over 18 years of age (based on the time when the informed consent form was signed) can be male or female;\n2. Subjects with gastrointestinal malignant tumor confirmed by histology\u002Fcytology;\n3. Subjects to be surgically removed or explored;\n4. The estimated survival time is ≥12 weeks;\n5. Subjects of childbearing age agreed to adopt effective contraceptive measures during the study period;\n6. Subjects fully understand the purpose, nature, methods and possible adverse reactions of the experiment, voluntarily participate in and sign a written informed consent, and are willing to follow the requirements of the protocol to complete the study.riteria:\n\nThose who meet one of the following items are not allowed to join the group:\n\n1. According to the researcher's judgment, during the screening period, from the imaging examination to the comprehensive real diagnosis information result, the patients were treated with anti-digestive tract tumor;\n2. symptomatic brain metastases who need treatment;\n3. Have serious cardiovascular and cerebrovascular diseases;\n4. There are other contraindications for imaging examination of the research plan, such as claustrophobia;\n5. Have a history of other malignant tumors;\n6. Pregnant (pregnancy test positive in screening period) or lactating women;\n7. Other circumstances that the researcher considers inappropriate to participate in this clinical trial.","ALL","18 Years",{"count":51,"type":52},90,"ESTIMATED","INTERVENTIONAL",[55],"PHASE2","The main purpose of this study is to evaluate the effectiveness of technetium \\[99mTc\\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To evaluate the safety of technetium \\[99mTc\\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To explore the diagnostic threshold of technetium \\[99mTc\\]-H7ND injection for peritoneal metastasis of gastrointestinal malignant tumor.",[58,59],"Solid Tumor","Peritoneal Metastasis","2025-08-04",{"date":62,"type":63},"2025-08-06","ACTUAL",{"date":65,"type":63},"2025-03-12",{"date":67,"type":52},"2025-09",{"name":5,"class":6},1]